Literature DB >> 34751175

Discriminative stimulus properties of the 5-HT1A receptor biased agonists NLX-101 and F13714, in rats trained to discriminate 8-OH-DPAT from saline.

Jillian H Broadbear1,2, Ronan Y Depoortere3, Kristina Vacy2,4, David Ralph2, Brendan J Tunstall2,5, Adrian Newman-Tancredi3.   

Abstract

NLX-101 and F13714 are selective, full efficacy, biased agonists of the serotonin (5-HT1A) receptor. NLX-101 preferentially activates cortical postsynaptic 5-HT1A receptors, whereas F13714 preferentially activates raphe nuclei presynaptic 5-HT1A receptors. We compared NLX-101 and F13714 for their efficacy and potency to substitute for the discriminative cue produced by the prototypical, nonbiased 5-HT1A receptor agonist 8-OH-DPAT (racemate). Male and female Sprague-Dawley rats were trained to discriminate 8-OH-DPAT (0.1 mg/kg i.p., 20 min pretreatment) from saline using a classical two-lever drug-discrimination procedure. 8-OH-DPAT (0.01 and 0.05 mg/kg i.p.) dose-dependently substituted for the training dose, with about 50% responding on the 8-OH-DPAT-associated lever at 0.05 mg/kg. F13714 fully and very potently substituted for the training dose of 8-OH-DPAT from 0.018 mg/kg i.p., whereas NLX-101 only achieved full substitution at 0.5 mg/kg i.p., a dose which is known to also activate presynaptic 5-HT1A receptors. The 5-HT1A receptor partial agonist, buspirone, partially substituted (~80%) at 1 and 2 mg/kg i.p., doses which also decreased response rates. F13714 decreased response rates at 0.05 mg/kg. The selective 5-HT1A receptor antagonist WAY-100 635 (1 mg/kg s.c., 40 min pretreatment) elicited almost no responding on the 8-OH-DPAT-associated lever by itself, but blocked the discriminative stimulus effects produced by administration (20 min pretreatment) of 8-OH-DPAT (0.1 mg/kg), F13714 (0.025 mg/kg), NLX-101 (0.5 mg/kg) or buspirone (1 mg/kg). These data suggest that the discriminative cue produced by 0.1 mg/kg i.p. 8-OH-DPAT results from activation of presynaptic 5-HT1A receptors. They also further demonstrate the distinct profiles in behavioral models of 5-HT1A receptor-biased agonists.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34751175      PMCID: PMC8589115          DOI: 10.1097/FBP.0000000000000659

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  28 in total

1.  Determination of brain concentrations of 8-hydroxy-2-(di-n-propylamino)tetralin by liquid chromatography with electrochemical detection.

Authors:  K W Perry; R W Fuller
Journal:  Biochem Pharmacol       Date:  1989-10-01       Impact factor: 5.858

2.  Divergent effects of the 'biased' 5-HT1 A receptor agonists F15599 and F13714 in a novel object pattern separation task.

Authors:  N P van Goethem; R Schreiber; A Newman-Tancredi; M Varney; J Prickaerts
Journal:  Br J Pharmacol       Date:  2015-02-27       Impact factor: 8.739

3.  The discriminative stimulus properties of buspirone involve dopamine-2 receptor antagonist activity.

Authors:  H J Rijnders; J L Slangen
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

4.  Selective interaction of novel anxiolytics with 5-hydroxytryptamine1A receptors.

Authors:  S J Peroutka
Journal:  Biol Psychiatry       Date:  1985-09       Impact factor: 13.382

5.  Discriminative stimulus properties of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OHDPAT): implications for understanding the actions of novel anxiolytics.

Authors:  K A Cunningham; P M Callahan; J B Appel
Journal:  Eur J Pharmacol       Date:  1987-06-12       Impact factor: 4.432

6.  Discriminative stimulus properties of 8-OH-DPAT in rats are not altered by pretreatment with para-chlorophenylalanine.

Authors:  H O Kalkman
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

7.  Studies of the biochemical basis for the discriminative properties of 8-hydroxy-2-(di-n-propylamino)tetralin.

Authors:  R A Rabin; J C Winter
Journal:  Eur J Pharmacol       Date:  1993-04-28       Impact factor: 4.432

Review 8.  International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function.

Authors:  Nicholas M Barnes; Gerard P Ahern; Carine Becamel; Joël Bockaert; Michael Camilleri; Severine Chaumont-Dubel; Sylvie Claeysen; Kathryn A Cunningham; Kevin C Fone; Michael Gershon; Giuseppe Di Giovanni; Nathalie M Goodfellow; Adam L Halberstadt; Rachel M Hartley; Ghérici Hassaine; Katharine Herrick-Davis; Ruud Hovius; Enza Lacivita; Evelyn K Lambe; Marcello Leopoldo; Finn Olav Levy; Sarah C R Lummis; Philippe Marin; Luc Maroteaux; Andrew C McCreary; David L Nelson; John F Neumaier; Adrian Newman-Tancredi; Hugues Nury; Alexander Roberts; Bryan L Roth; Anne Roumier; Gareth J Sanger; Milt Teitler; Trevor Sharp; Carlos M Villalón; Horst Vogel; Stephanie W Watts; Daniel Hoyer
Journal:  Pharmacol Rev       Date:  2021-01       Impact factor: 25.468

9.  Anti-aggressive effects of the selective high-efficacy 'biased' 5-HT₁A receptor agonists F15599 and F13714 in male WTG rats.

Authors:  Sietse F de Boer; Adrian Newman-Tancredi
Journal:  Psychopharmacology (Berl)       Date:  2015-12-23       Impact factor: 4.530

10.  Selective serotonin 5-HT1A receptor biased agonists elicitdistinct brain activation patterns: a pharmacoMRI study.

Authors:  G Becker; R Bolbos; N Costes; J Redouté; A Newman-Tancredi; L Zimmer
Journal:  Sci Rep       Date:  2016-05-23       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.